• Policy
• Will Boryung succeed in tackling Sprycel’s patent
• by Lee, Tak-Sun Dec 30, 2021 05:51am

• Policy
• The MFDS plans to approve Daewoong's Fexuprazan
• by Lee, Tak-Sun Dec 30, 2021 05:51am

• Policy
• Paxlovid is a new weapon added to our fight against COVID-19
• by Lee, Jeong-Hwan Dec 29, 2021 05:58am

• Policy
• Gov-National Assembly introduce oral treatment for COVID-19
• by Lee, Jeong-Hwan Dec 29, 2021 05:57am

• Policy
• Entry of FDA-approved new Chinese blood cancer drug imminent
• by Lee, Tak-Sun Dec 28, 2021 05:51am

• Policy
• MFDS approves emergency use of Pfizer’s oral COVID-19 drug
• by Lee, Tak-Sun Dec 28, 2021 05:50am

• Policy
• AstraZeneca Xigduo’s latecomers consecutively approved
• by Lee, Tak-Sun Dec 27, 2021 05:57am

• Policy
• Roche applies for approval of its new drug faricimab
• by Lee, Tak-Sun Dec 27, 2021 05:56am

• Policy
• The suspension of execution for Legalon has been extended
• by Kim, Jung-Ju Dec 27, 2021 05:56am

• Policy
• What are the variables for the release of Forxiga+ Januvia?
• by Lee, Tak-Sun Dec 24, 2021 05:49am